Xenon Pharmaceuticals (XENE) Return on Capital Employed (2014 - 2026)
Xenon Pharmaceuticals (XENE) reported Return on Capital Employed of 42.53% for Q1 2026, down 287.0% year-over-year from 22.75% in Q1 2025, and up 34.02% quarter-over-quarter from 64.47% in Q4 2025.
Xenon Pharmaceuticals (XENE) Return on Capital Employed (2014 - 2026) Analysis & Trends
Xenon Pharmaceuticals (XENE) has 13 years of Return on Capital Employed data on file, last reported at 42.53% in Q1 2026.
- Return on Capital Employed for Q1 2026 came in at 42.53%, down 287.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 42.53% (down 287.0% YoY), and the FY2025 annual result was 55.36%, down 2234.0% from the prior year.
- Return on Capital Employed climbed to 42.53% in Q1 2026 per XENE's latest filing, from 64.47% in the prior quarter.
- Over five years, Return on Capital Employed peaked at 4.06% in Q1 2022 and troughed at 64.47% in Q4 2025.
- A 5-year average of 29.98% and a median of 27.61% in 2023 frame the typical range for Return on Capital Employed.
- The sharpest annual moves came in 2022 and 2025: Return on Capital Employed jumped 1018 bps in 2022, then sank 2872 bps in 2025.
- A 5-year view of Return on Capital Employed shows it stood at 17.4% in 2022, then tumbled by 56 bps to 27.07% in 2023, then sank by 32 bps to 35.74% in 2024, then sank by 80 bps to 64.47% in 2025, then jumped by 34 bps to 42.53% in 2026.
- Business Quant data shows XENE's Return on Capital Employed at 42.53% in Q1 2026, 64.47% in Q4 2025, and 56.54% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 450.31% |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 51.73% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -107.40% |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 21.10% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -50.43% |
| 10 | Xenon Pharmaceuticals | 4.61 Bn | 4.61 Bn | - | -42.53% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -42.53% |
| Dec 31, 2025 | -64.47% |
| Sep 30, 2025 | -56.54% |
| Jun 30, 2025 | -47.08% |
| Mar 31, 2025 | -39.66% |
| Dec 31, 2024 | -35.74% |
| Sep 30, 2024 | -30.78% |
| Jun 30, 2024 | -27.29% |
| Mar 31, 2024 | -24.36% |
| Dec 31, 2023 | -27.07% |
| Sep 30, 2023 | -31.18% |
| Jun 30, 2023 | -27.61% |
| Mar 31, 2023 | -22.51% |
| Dec 31, 2022 | -17.40% |
| Sep 30, 2022 | -6.82% |
| Jun 30, 2022 | -4.55% |
| Mar 31, 2022 | -4.06% |
| Dec 31, 2021 | -5.27% |
| Sep 30, 2021 | -17.00% |
| Jun 30, 2021 | -14.10% |